Cvfg LLC Invests $2.96 Million in Phibro Animal Health Corporation $PAHC

Cvfg LLC bought a new position in Phibro Animal Health Corporation (NASDAQ:PAHC) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 53,560 shares of the company’s stock, valued at approximately $2,962,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. 1620 Investment Advisors Inc. lifted its holdings in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the last quarter. Tudor Investment Corp ET AL boosted its position in shares of Phibro Animal Health by 3.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after purchasing an additional 338 shares during the period. JPMorgan Chase & Co. increased its stake in Phibro Animal Health by 2.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after buying an additional 386 shares during the period. Finally, Brooklyn Investment Group raised its holdings in Phibro Animal Health by 8.7% during the 4th quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock worth $255,000 after buying an additional 538 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Price Performance

Shares of PAHC opened at $33.12 on Wednesday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of 14.21, a P/E/G ratio of 0.48 and a beta of 0.46. Phibro Animal Health Corporation has a fifty-two week low of $25.58 and a fifty-two week high of $60.08. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The business’s 50-day moving average is $35.64 and its 200-day moving average is $43.71.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities research analysts expect that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the transaction, the chief executive officer directly owned 67,720 shares of the company’s stock, valued at approximately $3,778,776. This represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 46,768 shares of company stock worth $2,560,222. Insiders own 50.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on PAHC shares. Citigroup decreased their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and an average target price of $42.50.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.